Search results

...用]]は、[[anosmia/ja|嗅覚の喪失]]と関連している；その結果、2009年6月、[[:en:United States Food and Drug Administration|米国食品医薬品局]]（USFDA）は、経鼻亜鉛の使用を中止するよう消費者に警告した。 == 安全性{{Anchor|Safety}}== ...

...sense of smell]]; consequently, in June 2009, the [[United States Food and Drug Administration]] (USFDA) warned consumers to stop using intranasal zinc. == Safety == ...

薬物クラス（'''drug class'''）とは、類似した[[chemical structure/ja|化学構造]]を持ち、同じ[[mechanism of action/j 薬物クラスは通常、[[prototype drug/ja|プロトタイプ薬物]]によって定義され、最も重要で、通常はそのクラス内で最初に開発された薬物であり、比較の基準として使用される。 ...

...sense of smell]]; consequently, in June 2009, the [[United States Food and Drug Administration]] (USFDA) warned consumers to stop using intranasal zinc. == Safety == ...

==安全性に関する懸念{{Anchor|Safety concerns}}== 米国[[Food and Drug Administration/ja|食品医薬品局]]（FDA）は、グルコン酸亜鉛を適正製造規範に従って使用すれば[[generally recogni ...

{{Short description|Category of drugs used to classify a drug according to certain criteria}} A '''drug class''' is a set of [[medication]]s and other compounds that have a simila ...

...t of bulk drug substances due to a lack of clinical evidence regarding its safety and efficacy. ...t 7-Keto-DHEA be included among substances banned from use in [[compounded drug]]s. ...

{{Short description|Category of drugs used to classify a drug according to certain criteria}} A '''drug class''' is a set of [[medication]]s and other compounds that have a simila ...

...t of bulk drug substances due to a lack of clinical evidence regarding its safety and efficacy. ...t 7-Keto-DHEA be included among substances banned from use in [[compounded drug]]s. ...

==Safety concerns== The U.S. [[Food and Drug Administration]] (FDA) considers zinc gluconate to be [[generally recognize ...

==Safety concerns== The U.S. [[Food and Drug Administration]] (FDA) considers zinc gluconate to be [[generally recognize ...

...% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug) ...s a result, the FDA required an additional safety clinical trial after the drug was approved and on the market to better understand these differences, and ...

...% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug) ...s a result, the FDA required an additional safety clinical trial after the drug was approved and on the market to better understand these differences, and ...

...gnancy) and Appendix 5 (breast feeding) is now available in the individual drug monographs.<ref>British National Formulary, online January 2016</ref> ...tion of a "pregnancy category". These rules are enforced by the [[Food and Drug Administration]]. ...

...列]]を変化させ、その[[ADME/ja|ADME]]（吸収、分布、代謝、排泄）特性を変えることができる。 公式には、[[U.S. Food and Drug Administration/ja|米国食品医薬品局]]（FDA）はこれらの薬物を'''インスリン受容体リガンド'''（インスリンそのものと同様に、[ {{Anchor|Research on safety, efficacy, and comparative effectiveness}} ...

{{Drug List/ja|state6=uncollapsed}} ...-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} ...

...]], [[semaglutide]], and [[tirzepatide]] are approved by the US [[Food and Drug Administration]] (FDA) for weight management in combination with reduced-ca ...s FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. ...

{{Infobox drug ...l nonproprietary name|INN]], trade names '''Suglat''') is a pharmaceutical drug for treatment of [[Diabetes mellitus type 2|type 2 diabetes]]. Ipragliflozi ...

{{Infobox drug ...l nonproprietary name|INN]], trade names '''Suglat''') is a pharmaceutical drug for treatment of [[Diabetes mellitus type 2|type 2 diabetes]]. Ipragliflozi ...

...]], [[semaglutide]], and [[tirzepatide]] are approved by the US [[Food and Drug Administration]] (FDA) for weight management in combination with reduced-ca ...s FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. ...